Skip to content

Low-dose Droperidol for Prevention of Postoperative Delirium in Elderly Patients After Non-cardiac Surgery

Low-dose Droperidol for Prevention of Postoperative Delirium in Elderly Patients After Non-cardiac Surgery: A Randomized, Double-blind, Placebo-controlled Trial

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05401058
Enrollment
797
Registered
2022-06-02
Start date
2022-11-21
Completion date
2025-07-30
Last updated
2026-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System Disease, Gynecological Disease, Orthopedic Surgery, Urologic Diseases

Keywords

non-cardiac surgery, Droperidol, postoperative delirium, elderly patients

Brief summary

The aim of this multicenter, prospective, randomized, double-blind and large sample study is to explore the preventive effect of low-dose droperidol on POD in elderly patients after non-cardiac surgery, providing new approach for reducing the incidence of POD and improving the prognosis and quality of life.

Interventions

About 30min before the end of operation, Droperidol 1.25mg/0.5ml will be administered by intravenous injection.

DRUGSaline

About 30min before the end of operation, Normal saline 0.5ml will be administered by intravenous injection.

Sponsors

RenJi Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age≥65 years * American Society of Anesthesiologists (ASA): I-III * Planning to undergo elective non-cardiac surgery under general anesthesia with endotracheal intubation, including digestive, orthopedic, urologic and gynecological surgery * Estimated operation time more than 2 hours * Not expected to be admitted to ICU postoperatively * Proficient in Chinese * Informed consent

Exclusion criteria

* Morbid obesity with BMI \>35 kg/m2; * History of psychological and neurological diseases, such as depression, schizophrenia, epilepsy, severe central nervous system depression, Parkinson's disease, Alzheimer's disease, myasthenia gravis, basal ganglia disease, etc; * Corrected QT (QTc) of electrocardiogram\> 500ms; * Preoperative liver insufficiency (Child Pugh grade C); * End-stage renal disease requiring dialysis; * Severe heart failure \[Metablic equivalent (METs)\<4\]; * Allergic to droperidol; * Inability to communicate due to coma or dementia in preoperative period; * Preoperative delirium, assessed by 3D-CAM; * More than three standard alcoholic drinks per day (≈10 g alcohol , equivalent to 50 g of strong Chinese spirits); * Participating in conflicting clinical trials; * Expected to have an additional operation within 7 days after the index operation.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of delirium within 7 days after operation7 days after operationIncidence of delirium within 7 days after operation

Secondary

MeasureTime frameDescription
Severity of deliriumFrom the end of operation to 7 days after opertationSeverity of Postoperative delirium
Delirium-free daysFrom the end of operation to 7 days after opertationDelirium-free days
Postoperative hospital durationFrom end of operation to discharge, an average of 1 weekPostoperative hospital duration
cognitive function at 30 days and 6 months30 days and 6 months after surgerycognitive function at 30 days and 6 months

Countries

China

Contacts

STUDY_CHAIRDiansan Su, MD,PHD

First Affiliated Hospital of Zhejiang University

PRINCIPAL_INVESTIGATORZiyu Zhu, MD,PHD

Renji Hospital, Jiaotong University, School of medicine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 13, 2026